Table 3.

Duration of intracranial tumor response and intracranial PFS by IRC assessment in patients with RET fusion-positive NSCLC and measurable and nonmeasurable intracranial disease.

Total patients (N = 80)
Duration of intracranial response
 Respondersa38
 Censored, n (%)b27 (71)
 Intracranial DoR, median (months) (95% CI)c,dNE (9.3–NE)
 Intracranial duration of follow-up, median (months) (IQR)c9.5 (5.7, 12.0)
 Intracranial DoRc,e
  % of patients ≥6 months (95% CI)91 (75–97)
  % of patients ≥12 months (95% CI)55 (32–73)
PFS
 Censored, n (%)b50 (62.5)
 Median, months (95% CI)c,d13.7 (10.9–NE)
 Median follow-up, (months) (IQR)c11.0 (7.4, 16.5)
 % progression/death-freec,e
  ≥6 months (95% CI)79 (68–87)
  ≥12 months (95% CI)55 (41–67)
  • Abbreviation: NE, not estimable.

  • aPatients with intracranial best response of CR or PR based on IRC assessments using RECIST (version 1.1).

  • bStatus as of the patient's last disease assessment on or before December 16, 2019.

  • cEstimate based on Kaplan–Meier method.

  • d95% CI was calculated using Brookmeyer and Crowley method.

  • e95% CI was calculated using Greenwood formula.